CYTK
Price
$34.66
Change
+$0.30 (+0.87%)
Updated
Jul 3 closing price
Capitalization
4.14B
26 days until earnings call
RNA
Price
$29.17
Change
-$0.19 (-0.65%)
Updated
Jul 3 closing price
Capitalization
3.52B
38 days until earnings call
Interact to see
Advertisement

CYTK vs RNA

Header iconCYTK vs RNA Comparison
Open Charts CYTK vs RNABanner chart's image
Cytokinetics
Price$34.66
Change+$0.30 (+0.87%)
Volume$1.3M
Capitalization4.14B
Avidity Biosciences
Price$29.17
Change-$0.19 (-0.65%)
Volume$553.95K
Capitalization3.52B
CYTK vs RNA Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. RNA commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (CYTK: $34.66 vs. RNA: $29.17)
Brand notoriety: CYTK and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 71% vs. RNA: 41%
Market capitalization -- CYTK: $4.14B vs. RNA: $3.52B
CYTK [@Biotechnology] is valued at $4.14B. RNA’s [@Biotechnology] market capitalization is $3.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than RNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while RNA’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 3 bearish.
  • RNA’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than RNA.

Price Growth

CYTK (@Biotechnology) experienced а +2.21% price change this week, while RNA (@Biotechnology) price change was -2.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

RNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.14B) has a higher market cap than RNA($3.52B). RNA YTD gains are higher at: 0.309 vs. CYTK (-26.318). RNA has higher annual earnings (EBITDA): -430.35M vs. CYTK (-513.62M). RNA has more cash in the bank: 1.38B vs. CYTK (938M). RNA has less debt than CYTK: RNA (5.97M) vs CYTK (791M). CYTK has higher revenues than RNA: CYTK (19.2M) vs RNA (8.93M).
CYTKRNACYTK / RNA
Capitalization4.14B3.52B118%
EBITDA-513.62M-430.35M119%
Gain YTD-26.3180.309-8,504%
P/E RatioN/AN/A-
Revenue19.2M8.93M215%
Total Cash938M1.38B68%
Total Debt791M5.97M13,241%
FUNDAMENTALS RATINGS
CYTK: Fundamental Ratings
CYTK
OUTLOOK RATING
1..100
25
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
83
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYTKRNA
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGVRX45.080.51
+1.14%
JPMorgan Growth Advantage R5
DGEYX23.150.20
+0.87%
BNY Mellon Global Emerging Mkts - Y
FSRPX19.570.16
+0.82%
Fidelity Select Retailing
PJDZX18.230.10
+0.55%
PGIM Jennison Rising Dividend Z
IVOYX19.470.05
+0.26%
Macquarie Mid Cap Income Opps Y

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with ACLX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
-0.65%
ACLX - RNA
59%
Loosely correlated
+1.24%
DYN - RNA
56%
Loosely correlated
-2.01%
OCUL - RNA
52%
Loosely correlated
+1.69%
CRNX - RNA
52%
Loosely correlated
+1.22%
STOK - RNA
51%
Loosely correlated
-0.61%
More